
    
      PRIMARY OBJECTIVES:

      I. To evaluate the anti-tumor efficacy of targeted agents or checkpiont inhibitors in
      advanced stage NSCLC with genomic alteration.

      SECONDARY OBJECTIVES:

      I. To evaluate the clinical efficacy of targeted agents or checkpiont inhibitors in advanced
      stage NSCLC with genomic alteration.

      II. To evaluate safty and tolerence of targeted agents or checkpiont inhibitors in advanced
      stage NSCLC with genomic alteration.
    
  